Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) EBT (2018 - 2025)

Historic EBT for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to -$7.1 million.

  • Exagen's EBT fell 4093.08% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.0 million, marking a year-over-year decrease of 1240.09%. This contributed to the annual value of -$15.1 million for FY2024, which is 3615.57% up from last year.
  • According to the latest figures from Q3 2025, Exagen's EBT is -$7.1 million, which was down 4093.08% from -$4.4 million recorded in Q2 2025.
  • Exagen's 5-year EBT high stood at -$3.0 million for Q2 2024, and its period low was -$15.1 million during Q4 2022.
  • For the 5-year period, Exagen's EBT averaged around -$6.8 million, with its median value being -$6.2 million (2021).
  • Per our database at Business Quant, Exagen's EBT tumbled by 12886.12% in 2022 and then surged by 6582.82% in 2023.
  • Quarter analysis of 5 years shows Exagen's EBT stood at -$6.9 million in 2021, then plummeted by 119.79% to -$15.1 million in 2022, then soared by 63.35% to -$5.5 million in 2023, then soared by 32.33% to -$3.7 million in 2024, then tumbled by 89.01% to -$7.1 million in 2025.
  • Its last three reported values are -$7.1 million in Q3 2025, -$4.4 million for Q2 2025, and -$3.8 million during Q1 2025.